| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | AlteredExpression | disease | BEFREE | The analyses stress the importance of using a software which has the possibility to separate the level of a biochemical risk by correlating PAPP-A and free beta HCG and, by adding the NT marker, calculate the level of a final risk of Down syndrome. | 30581343 | 2018 | ||||
|
0.070 | Biomarker | disease | LHGDN | Human placental development is impaired by abnormal human chorionic gonadotropin signaling in trisomy 21 pregnancies. | 17690166 | 2007 | ||||
|
0.070 | GeneticVariation | disease | BEFREE | We present the case of a pregnant woman with low free beta-HCG in maternal serum Down syndrome screening that led to prenatal diagnosis of a fetus with 46,XY,der(4)t(4;11)(p14; q25). | 16231301 | 2005 | ||||
|
0.070 | AlteredExpression | disease | BEFREE | We concluded that in trisomy 21 the high tissue HCG concentration and expression of LH/HCG receptor in the trophoblast may reflect the relative immaturity of the trophoblastic tissue whereas in trisomy 18, the very low concentration of endogenous HCG, associated with an over-expression of LH/HCG receptor in the trophoblast, is probably secondary to the poor differentiation of the cytotrophoblast. | 10611254 | 2000 | ||||
|
0.070 | AlteredExpression | disease | BEFREE | The increase in hCG promoter activity in DS-derived fibroblasts suggests a possible role for a transcriptional factor located on the human chromosome 21 by either directly or indirectly interacting with the beta5-promoter. | 10085509 | 1999 | ||||
|
0.070 | Biomarker | disease | BEFREE | Significant correlations were found for AFP and UE3 in the controls and for intHCG and F beta HCG in both the control and the Down's syndrome pregnancies. | 8284287 | 1993 | ||||
|
0.070 | AlteredExpression | disease | BEFREE | The addition of two new markers in maternal serum, estriol and HCG, to those already known, namely the level of maternal serum alfa-fetoprotein and maternal age, considerably improves the expected results of a screening strategy for Down syndrome. | 1689225 | 1990 |